Extracellular ATP is among stimuli that potently activate NLRP3, therefore, it is very promising for therapeutic purposes the observation that deficiency of a single purinergic receptor, namely the P2X7 subtype, is sufficient to block NLRP3 inflammasome and ameliorate the clinical picture of atherosclerosis in mice (122). Here, P2RX1 is linked to atherosclerosis.